Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
Martin Moylan

Boston Scientific to pay $600M to settle suit over Guidant deal

Go Deeper.

Create an account or log in to save stories.

Log inCreate a free Account

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Show me!

Boston Scientific will pay $600 million to settle a fight over its 2006 purchase of Twin Cities-based Guidant Corp.

News of the settlement sent shares of Boston Scientific up nearly 12 percent in after-hours trading late Tuesday afternoon.

Boston Scientific beat out rival Johnson & Johnson to take over Guidant, paying $27 billion. It turned out that Guidant brought with it a slew of legal and other problems. Even so, Johnson & Johnson sued for $7 billion, accusing Guidant of welching on a prior merger agreement with J&J.

Under the settlement, Johnson & Johnson will dismiss the suit, and Boston Scientific won't accuse J&J of patent violations involving a family of products.

Boston Scientific has about 5,000 Minnesota employees and says the settlement is in the best interests of the company and shareholders.